republic-os/legislation/us/states/de/153/sb-129.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO PRESCRIPTION OPIOID FUNDS AND LITIGATION AUTHORITY.	Senate Bill 166, passed in 2022, created the Prescription Opioid Impact Fund as part of an overall structure that would both maximize the monies paid by settling Opioids defendants to Delaware and to create a structure whereby those settlement monies could be managed and distributed on a statewide basis through a stakeholder-informed process. The complete legislation is found at Title 16 of the Delaware Code, Chapter 48B, Sections 4801B through 4809B. Chapter 48B applied to settlements with entities, and did not apply to bankruptcies. This is because the bankruptcy process itself extinguishes claims and thus provides the necessary “global peace” for settling parties. At the time SB 166 was passed, it was contemplated that, in the context of the Purdue Pharma bankruptcy, the Sackler family members would obtain this type of bankruptcy-style discharge and release. However, in the summer of 2024, the United States Supreme Court ruled that such a discharge was impermissible. This decision thus required that the states negotiate a non-bankruptcy settlement with the Sacklers, which the Delaware Department has since been pursuing diligently.	us/states/de	Delaware General Assembly	153	SB 129	Delaware SB 129 (153)	bill		enacted	Bryan Townsend Claire Snyder-Hall David P. Sokola Ray Seigfried Russell Huxtable Sarah McBride Spiros Mantzavinos Stephanie L. Hansen	0	7	2	2025-05-07	2025-07-21	openstates	ocd-bill/1c981c02-6a0e-4d35-a73b-c8aa9c86b056	https://legis.delaware.gov/BillDetail?LegislationId=142215	a529fba2492d408e4e3c8d871f32f502b0b9c12462414cd532d86ba8c7af1991	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-de

Delaware SB 129 (153) — AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO PRESCRIPTION OPIOID FUNDS AND LITIGATION AUTHORITY.

Senate Bill 166, passed in 2022, created the Prescription Opioid Impact Fund as part of an overall structure that would both maximize the monies paid by settling Opioids defendants to Delaware and to create a structure whereby those settlement monies could be managed and distributed on a statewide basis through a stakeholder-informed process. The complete legislation is found at Title 16 of the Delaware Code, Chapter 48B, Sections 4801B through 4809B. Chapter 48B applied to settlements with entities, and did not apply to bankruptcies. This is because the bankruptcy process itself extinguishes claims and thus provides the necessary “global peace” for settling parties. At the time SB 166 was passed, it was contemplated that, in the context of the Purdue Pharma bankruptcy, the Sackler family members would obtain this type of bankruptcy-style discharge and release. However, in the summer of 2024, the United States Supreme Court ruled that such a discharge was impermissible. This decision thus required that the states negotiate a non-bankruptcy settlement with the Sacklers, which the Delaware Department has since been pursuing diligently.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

Votes

• 3/5 — 39–0 (pass) · lower
• SM — 19–0 (pass) · upper

Sponsors

• Bryan Townsend — primary (person)
• Claire Snyder-Hall — primary (person)
• David P. Sokola — primary (person)
• Ray Seigfried — primary (person)
• Russell Huxtable — primary (person)
• Sarah McBride — primary (person)
• Spiros Mantzavinos — primary (person)
• Stephanie L. Hansen — primary (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2025-05-07 Introduced and Assigned to Health & Social Services Committee in Senate introduction, referral-committee
• 2025-05-14 Reported Out of Committee (Health & Social Services) in Senate with 8 Favorable committee-passage, committee-passage-favorable
• 2025-05-20 Passed By Senate. Votes: 19 YES 2 ABSENT passage
• 2025-05-21 Assigned to Health & Human Development Committee in House introduction, referral-committee
• 2025-06-11 Reported Out of Committee (Health & Human Development) in House with 5 Favorable, 5 On Its Merits committee-passage, committee-passage-favorable
• 2025-06-25 Passed By House. Votes: 39 YES 1 ABSENT 1 VACANT passage
• 2025-07-21 Signed by Governor executive-signature

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/1c981c02-6a0e-4d35-a73b-c8aa9c86b056. Confidence: reported (aggregated from official Delaware legislature records).